Pathways and therapeutic targets in melanoma - Test2 - elhamkhani - TriplyDB

Pathways and therapeutic targets in melanoma

Pathways and therapeutic targets in melanoma

http://www.wikidata.org/entity/Q26865736

about

The MST/Hippo Pathway and Cell Death: A Non-Canonical Affair Novel Drugs and Combination Therapies for the Treatment of Metastatic Melanoma Oncogenomic portals for the visualization and analysis of genome-wide cancer data Adapt, Recycle, and Move on: Proteostasis and Trafficking Mechanisms in Melanoma Metabolic rewiring in melanoma Systems Analysis of Adaptive Responses to MAP Kinase Pathway Blockade in BRAF Mutant Melanoma.Registered Report: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas.Acute Inhibition of MEK Suppresses Congenital Melanocytic Nevus Syndrome in a Murine Model Driven by Activated NRAS and Wnt Signaling.Wogonin suppresses melanoma cell B16-F10 invasion and migration by inhibiting Ras-medicated pathways.Selenocysteine derivative overcomes TRAIL resistance in melanoma cells: evidence for ROS-dependent synergism and signaling crosstalk.A highly efficient tumor-infiltrating MDSC differentiation system for discovery of anti-neoplastic targets, which circumvents the need for tumor establishment in mice.Animal models and therapeutic molecular targets of cancer: utility and limitations.MITF in melanoma: mechanisms behind its expression and activity.Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma The CASC15 Long Intergenic Noncoding RNA Locus Is Involved in Melanoma Progression and Phenotype Switching Deep-proteome mapping of WM-266-4 human metastatic melanoma cells: From oncogenic addiction to druggable targets Pharmacological targeting of guanosine monophosphate synthase suppresses melanoma cell invasion and tumorigenicity.Serum CEACAM1 Elevation Correlates with Melanoma Progression and Failure to Respond to Adoptive Cell Transfer Immunotherapy.Nucleotide excision repair deficiency in melanoma in response to UVA.Fisetin, a dietary flavonoid, augments the anti-invasive and anti-metastatic potential of sorafenib in melanoma.Antibiotic drug tigecycline inhibits melanoma progression and metastasis in a p21CIP1/Waf1-dependent manner.Microsomal PGE2 synthase-1 regulates melanoma cell survival and associates with melanoma disease progression.Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells Parthenolide induces MITF-M downregulation and senescence in patient-derived MITF-M(high) melanoma cell populations Pterostilbene Decreases the Antioxidant Defenses of Aggressive Cancer Cells In Vivo: A Physiological Glucocorticoids- and Nrf2-Dependent Mechanism Advances in immunotherapy for melanoma management.Pharmacological interventions for melanoma: Comparative analysis using bayesian meta-analysis.Treating advanced melanoma: current insights and opportunities.Trametinib in the treatment of melanoma.Nivolumab in combination with ipilimumab for the treatment of melanoma.Prognostic and predictive biomarkers in melanoma: an update.Molecular Targeted Therapy Approaches for BRAF Wild-Type Melanoma.Nanoparticle-Based Celecoxib and Plumbagin for the Synergistic Treatment of Melanoma.Somatic driver mutations in melanoma.Epigenetic Regulation of KPC1 Ubiquitin Ligase Affects the NF-κB Pathway in Melanoma.Clinical and therapeutic implications of BRAF mutation heterogeneity in metastatic melanoma.Focus on cutaneous and uveal melanoma specificities.Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack.

P2860

Q26744308-8AF5CAA5-B72F-4893-BB8C-CE2DF5FCA447 Q26772015-6A1855C1-887C-4E7B-9530-5A84A7AF5354 Q26781295-5F546821-047C-4444-90F0-3F82FE678103 Q28069018-FCB0A9DB-B6FF-4207-9040-6CF738A1BEA0 Q28069081-EA9707C8-45DE-462A-A780-7A9BE198CD0B Q28548486-791F6E9B-8FCD-4470-BB7B-A90DB33FE99C Q28601717-9AD20E26-ADB6-4BC3-B06C-7CE787677E7E Q29615443-27D04175-9B6C-4C65-A424-36672AE3C0ED Q30277902-E71D031E-C469-40BD-B4E5-1C17875F62F8 Q30661575-CF7BD0B5-0895-4398-9E63-DA595250169C Q34155733-4E987C1C-1990-40EC-A2B3-69176544B999 Q34365708-C8EF1B19-9629-4721-B764-69E05058E743 Q34365909-4A321EC7-10A4-4DDE-B1FD-C6D246C5180D Q34386828-B42321EB-514A-491C-98FC-ED6B31E54A5E Q35187734-F54CC4D9-0999-4AE8-BF8E-1D5733E4CFF0 Q35741539-552ABEBD-7B8B-4B43-8427-220774EC00AE Q36054438-BA3328C4-7A8C-4F17-B6BE-26FCDA94EE8B Q36270042-A600523A-DE5D-4E58-ABE9-FAE531A343D7 Q36288343-B52E8807-D57F-4246-8B9F-49A7CD69C2BF Q36356547-F4C7A171-24AE-4DC9-BD42-8FE1F8BC8047 Q36612048-AE3FE105-E48E-4AEA-99BA-8DF1238FA6BE Q36738788-BD059E05-3EC5-4D87-8DFF-658DBA0C9F58 Q36772071-7C3CC9CD-218B-4550-A80C-76CB30AF50BC Q36823360-1DAAFCAA-A699-4E4B-B59D-382B12D5DCE8 Q36916468-C8A9D3CA-17EA-4BF5-A468-6B77FEE62D67 Q36962495-93025CB0-F53E-4968-9DC9-C0C6385BF324 Q37040056-4F61CB5D-947B-4384-A604-D3366E06A44B Q37375978-71D4CAC2-F5AE-47E8-8B76-8E356406E7F6 Q37697084-E9C709AF-C15E-45BE-AFA1-72B140743443 Q38250316-9010E091-2405-4611-B9EB-B3BCC078F7FD Q38392273-F61B4B2E-9431-460C-BDC6-4066F05C0942 Q38592160-2F81770A-63D9-4648-B20D-A337C3EC0D57 Q38653619-8D3805D9-FC19-4AFE-8052-B1D0C8E50B52 Q38689912-197EE5F7-5A48-45A3-BF35-38BC1020A326 Q38724921-9EA39AD6-37BE-4308-8A42-318852CA2C9B Q38764368-35F997F4-CB47-4630-B450-CAA2DE1CD7A5 Q38847201-6F26BF95-8EBD-4A09-AFDD-E77BC4EF292A Q39077390-AFF34E39-5B0D-43BA-807D-6F5DD046A46E Q39312161-95147651-6AD5-4DA9-8DF9-783A0EC25320 Q39312652-AFADB7B0-A161-4163-BBFA-FA90CCA66D25

P2860

Pathways and therapeutic targets in melanoma

http://www.wikidata.org/entity/Q26865736

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Pathways and therapeutic targets in melanoma

@ast

Pathways and therapeutic targets in melanoma

@en

Pathways and therapeutic targets in melanoma

@nl

type

label

Pathways and therapeutic targets in melanoma

@ast

Pathways and therapeutic targets in melanoma

@en

Pathways and therapeutic targets in melanoma

@nl

prefLabel

Pathways and therapeutic targets in melanoma

@ast

Pathways and therapeutic targets in melanoma

@en

Pathways and therapeutic targets in melanoma

@nl

P1433

Q26865736-C23829D0-866E-416C-BF49-E6F3BA6C1386

P1476

Q26865736-EA2FA0F7-C466-4D8D-B100-0ED9207AE9F6

P2093

Q26865736-07AA2A75-13C9-4A41-B023-DA0779853CDD

Q26865736-2F045BA2-53B6-4D04-A119-4A81E54AEC60

Q26865736-9A41B90F-75D0-41C5-AC99-026356F0A075

Q26865736-9F546050-261B-45A5-B947-B82F9E0DF83C

Q26865736-A209D07E-EB12-430A-BE60-482F27C07135

Q26865736-CB4CA186-B721-4F82-9A90-C9DAFC8061A3

Q26865736-CBE2E786-D4BE-4D1F-9298-E6A73C48C209

P275

Q26865736-0A75F338-4743-4F6E-9876-BF3AC99AE2B0

P2860

Q26865736-00799A8A-B78C-47B4-9C8F-84AB232D8B37

Q26865736-01CEC2F2-564B-4BD3-BB98-DBE6C2C2C773

Q26865736-024DEA8C-641D-4BC3-A14D-C0A8BC535340

Q26865736-02E5456F-DDF7-4828-A77C-349BA248E1EE

Q26865736-0304645D-C2D0-4C2A-BF2A-8B26A3EA53FA

Q26865736-03890317-D302-4B61-B800-723527C3A7C0

Q26865736-04B7661C-39FE-4E68-9385-2D0D44ADBE50

Q26865736-058E706C-0BE7-49A1-882B-AB24E86C0E19

Q26865736-06406CB0-4655-450B-800D-C3061F106807

Q26865736-06587AA6-2E8C-4725-9F18-ED1D090473CD

P304

Q26865736-45EA61B2-390A-4BED-AAE9-55358261EBF5

P31

Q26865736-63BC9B8D-7110-4B70-AF18-03140AFCA733

Q26865736-EC90C7A4-21CB-4591-ABE0-0DF24E7BCCAA

P3181

Q26865736-3965AAB4-65E3-4A72-B8E7-782415C512B6

P356

Q26865736-AA89B560-1EED-4242-9AEC-5EAFAD5FD3E8

P407

Q26865736-B902221E-6E54-4CD1-B204-CEB12E495988

P433

Q26865736-E7EB94C9-7B99-43CC-ADF9-C9F548F210F5

P478

Q26865736-F8D5169A-FC21-4809-A734-641C6B427CD1

P50

Q26865736-DAE5C344-5BCE-45E6-9CCE-1F52CA574AB8

P5008

Q26865736-41F330BF-695C-4C9F-AE41-C63A4DE76D94

P577

Q26865736-9E59B0E5-AD7A-41F3-AFBD-825AFCA8FC2E

P5875

Q26865736-4FF2059C-A6EC-4643-9683-75776ADCDECC

P698

Q26865736-54EFEFE7-675D-42BF-AD00-EAD4F4FD5A86

P921

Q26865736-79522807-50E1-438B-AE45-FE2C2430E612

P932

Q26865736-0DCFBB48-4BE5-4FA6-969D-08E004BD9571

P3181

P356

ONCOTARGET.1892

P1433

P1476

Pathways and therapeutic targets in melanoma

@en

P2093

David E. Fisher

http://www.w3.org/2001/XMLSchema#string

Emma Shtivelman

http://www.w3.org/2001/XMLSchema#string

James Yang

http://www.w3.org/2001/XMLSchema#string

Michael A. Davies

http://www.w3.org/2001/XMLSchema#string

Michal Lotem

http://www.w3.org/2001/XMLSchema#string

Moshe Oren

http://www.w3.org/2001/XMLSchema#string

Patrick Hwu

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 2.5 Unported

P2860

RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation

Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor

Regulation of MITF stability by the USP13 deubiquitinase

Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.

Cancer immunotherapy: moving beyond current vaccines

Inactivation of the NF1 gene in human melanoma and neuroblastoma cell lines without impaired regulation of GTP.Ras

Germline mutations in BAP1 predispose to melanocytic tumors

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients

P304

1701-52

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

691353

http://www.w3.org/2001/XMLSchema#string

P356

10.18632/ONCOTARGET.1892

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

P5008

P577

2014-04-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261756923

http://www.w3.org/2001/XMLSchema#string

P698

24743024

http://www.w3.org/2001/XMLSchema#string

P921

P932

4039128

http://www.w3.org/2001/XMLSchema#string